Isoxazolyl, oxazolyl, and thiazolylpropionic acid derivatives as potent α4β1 integrin antagonists
AJ Duplantier, GE Beckius, RJ Chambers… - Bioorganic & medicinal …, 2001 - Elsevier
AJ Duplantier, GE Beckius, RJ Chambers, LS Chupak, TH Jenkinson, AS Klein, KG Kraus…
Bioorganic & medicinal chemistry letters, 2001•ElsevierA series of isoxazolyl, oxazolyl, and thiazolylpropionic acid derivatives derived from LDV
was found to be a potent antagonist of the α4β1 integrin. The synthesis and SAR leading up
to 3-[3-(1-{2-[3-methoxy-4-(3-o-tolyl-ureido)-phenyl]-acetylamino}-3-methyl-butyl)-isoxazol-5-
yl]-propionic acid (22) are reported. In an allergic mouse model, compound 22 was
efficacious delivered systemically (58% inhib@ 10 mg/kg, sc) as well as by intra-tracheal
instillation (ED50= 2 μg/kg).
was found to be a potent antagonist of the α4β1 integrin. The synthesis and SAR leading up
to 3-[3-(1-{2-[3-methoxy-4-(3-o-tolyl-ureido)-phenyl]-acetylamino}-3-methyl-butyl)-isoxazol-5-
yl]-propionic acid (22) are reported. In an allergic mouse model, compound 22 was
efficacious delivered systemically (58% inhib@ 10 mg/kg, sc) as well as by intra-tracheal
instillation (ED50= 2 μg/kg).
A series of isoxazolyl, oxazolyl, and thiazolylpropionic acid derivatives derived from LDV was found to be a potent antagonist of the α4β1 integrin. The synthesis and SAR leading up to 3-[3-(1-{2-[3-methoxy-4-(3-o-tolyl-ureido)-phenyl]-acetylamino}-3-methyl-butyl)-isoxazol-5-yl]-propionic acid (22) are reported. In an allergic mouse model, compound 22 was efficacious delivered systemically (58% inhib @ 10 mg/kg, sc) as well as by intra-tracheal instillation (ED50=2 μg/kg).
Elsevier